Curriculum Vitae - iHealthSpot Interactive



CURRICULUM VITAE

Zunyan Dai, Ph.D.

Director

Cytogenetics and Molecular Genetics

Cell phone: 614-3715449

zunyan.dai@

CERTIFICATIONS:

Clinical Cytogenetics by the American Board of Medical Genetics, 2009

Clinical Molecular Genetics by the American Board of Medical Genetics, 2011

New York Certificate of Qualification as a laboratory director for clinical cytogenetics, molecular genetics and molecular oncology, New York Department of Health

CAP Inspector for cytogenetics, molecular genetics and molecular oncology

EDUCATION:

Aug. 1997 – Dec. 2002 Ph.D.

Division of Human Cancer Genetics and Department of Pathology, The Ohio State University.

Sept. 1993 – July 1996 Master degree

Basic and Clinical Oncology, Shanghai Medical University. P. R. China.

Sept. 1988 – July 1993 Bachelor degree

Medical Laboratory Technology, Shanghai Medical University. P. R. China.

PROFESSIONAL EXPERIENCES:

July 2017 - present

Scientific director at CSI laboratories, Cytogenetics and Molecular Genetics

Adjunct professor (application in process), Department of Human Genetics,

Emory University

December 2014 to June 2017

Cytogenetics consultant at CSI laboratories: cancer cytogenetics and FISH

October 2013 to June 2017 Emory University

Director, Cytogenetics, Molecular Genetics and Molecular Oncology

Senior director, July 2016 – June 2017

Clinical Assistant Professor

Emory Genetics Lab, Department of Human Genetics, Emory University

Review and report cases for conventional cytogenetics, FISH, microarrays for prenatal,

POC and postnatal, Sanger sequencing and NGS panels

July 2010 to September 2013

Technical Director, Cytogenetics, Molecular Genetics and Molecular Oncology, Quest Diagnostics Nichols Institute, Chantilly VA

Review and report cases for prenatal, postnatal, oncology genetic testing including

conventional cytogenetics, FISH, microarrays for POC, postnatal and cancer, and

molecular genetics and molecular oncology.

July 2009 to June 2010

Molecular Genetics Fellow at the Nationwide Children's Hospital and the Department of Pathology, The Ohio State University

July 2007 to June 2009

Cytogenetics Fellow at the Nationwide Children's Hospital and the Department of

Pathology, The Ohio State University

January 2003 to June 2007

Post-doctoral Research Associate, Program of Pharmacogenomics, Department of Pharmacology, The Ohio State University

I was involved in identifying genes that convey resistance or sensitivity to chemotherapy for human cancers in Dr. Wolfgang Sadee’s laboratory. Custom-built oligonucleotide microarrays were used for most of these studies. In addition, I established SNPlex panels to detect single nucleotide polymorphisms (SNPs) for candidate genes related to drug transportation, drug metabolism (Phase I and Phase II metabolism enzymes), cell cycle, cell growth and DNA repair. The SNPlex panels are expandable to include any other SNPs.

August 1997 to December 2002

Ph.D. Student, Department of Pathology, The Ohio State University

I conducted cancer research to discover the mechanisms of lung cancer development for better diagnosis and treatment in Dr. Christoph Plass’s laboratory, in the Division of Human Cancer Genetics. My Ph.D. work focused on DNA methylation changes and genetic alterations in human lung cancer.

September 1993 to July 1997, Liver Cancer Institute, Medical School, Fudan University (former Shanghai Medical University)

For a Master of Science degree, I focused on a clinical trial for the treatment of Hepatocellular Carcinoma, one of the most prevalent cancer types in China. After graduation in 1996, I worked there for one year to continue the research. I was trained as a resident to treat liver cancer patients for one year.

TEACHING EXPERIENCES:

2013 to present, Teaching Clinical Molecular Genetics and Cytogenetics Fellows, Genetic Counseling Students and Medical Students at Emory University

2010 to 2013 at Quest Diagnostics, Pathology Residents and Genetics Fellows from NIH, Georgetown University, Hershey Medical Center, University of Puerto Rico and Temple University

2008, 2009 and 2010, Pathology 670 (Medical Cytogenetics) at The Ohio State University

Autumn Quarter 2004 and Winter Quarter 2005, Molecular Genetics 602 at The Ohio State University: Laboratory Exercises: Eukaryotic Cell and Developmental Biology Laboratory for Mrs. Shannon Schraegle

MEMBERSHIPS:

Active Membership of the Association for Molecular Pathology

Active Membership of the American Association for Cancer Research

Active Membership of the American Society of Human Genetics

The OSU Chapter of the National Honor Society of Phi Kappa Phi

AWARDS:

2003 Gradate Student of the Year Award, Department of Pathology, The Ohio State University.

2002 Presidential Fellowship, The Ohio State University.

2001 Outstanding Paper and Second Place Presentation on 15th annual Edward F. Hayes graduate research forum. The Ohio State University, April 21, 2001.

1998. Graduate School Fellowship. The Ohio State University.

1993. People’s Scholarship for Outstanding Personality and Studies from Shanghai Medical University.

1992. Guanghua Scholarship for Outstanding Personality and Studies, which is available to top 5% students in Shanghai Medical University.

1991. University Outstanding Student in Recognition of Superior Characters, Excellent Studies and Good health.

People’s Scholarship for Outstanding Personality and Studies from Shanghai Medical University.

1990. People’s Scholarship for Outstanding Personality and Studies from Shanghai Medical University.

REVIEWER FOR INTERNATIONALLY CIRCULATED JOURNALS:

Cancer Genetics

Cell Research

European Journal of Cancer

Experimental Lung Research

International Journal of Cancer

The Journal of Molecular Diagnostics

Journal of Pharmacology and Experimental Therapeutics

The Journal of Hematology & Oncology

Journal of Cancer Research

Molecular Cytogenetics

Neoplasia

Pharmaceutical Research

PLoS ONE

INVITED LECTURE:

Dai Z, Colorectal Cancer Testing and the RAS pathway in Targeted Therapy, Annual meeting of West Virginia Association of Pathologists, Wheeling, WV, May 7, 2011

BOOK CHAPTER:

Zunyan Dai, Kavitha Kosuri and Gregory A. Otterson, Mechanisms of DNA demethylating drugs against cancer progression, In: DNA Methylation, Epigenetics and Metastasis. Editor. Manel Esteller, M.D., Ph.D. Springer Publisher, Printed in Netherlands. 2005, Pages 243-267.

PROFESSIONAL PUBLICATIONS:

1. Dai Z, Zachary Whitt Z, Mighion LC, Pontoglio A, Bean LJH, Colombo R, Hegde M. Caution in Interpretation of Disease Causality for Heterozygous Loss-of-function Variants in the MYH8 Gene, European Journal of Medical Genetics, 2017 Jun;60(6):312-316

2. Xue Y, Shankar S, Cornell K, Dai Z, Wang CE, Rudd MK, Coffee B. Paternal Duplication of the 11p15 Centromeric Imprinting Control Region is Associated with Increased Expression of CDKN1C in a Child with Russell-Silver Syndrome. American Journal of Medical Genetics Part A, Am J Med Genet A. 2015 Dec; 167(12):3229-33.

3. McDermott DH, Gao JL, Liu Q, Siwicki M, Martens C,, Jacobs P, Velez D, Yim E, Bryke CR, Hsu N, Dai Z, Marquesen MM, Stregevsky E, Kwatemaa N, Theobald N, Long Priel DA, Pittaluga S, Raffeld MA, Calvo KR, Maric I, Desmond R, Holmes KL, Kuhns DB, Balabanian K, Bachelerie F, Porcella SF, Malech HL, Murphy PM. Chromothriptic Cure of WHIM Syndrome. Cell, 2015 Feb 12;160(4):686-99

4. Wheeler PG, Huang D and Dai Z, Haploinsufficiency of HDAC4 does not cause intellectual disability in all affected individuals. Am. J. Med. Genet. A, 2014 Jul; 164(7):1826-9.

5. Salpea P, Horvath A, London E, Faucz FR, Vetro A, Levy I, Gourgari E, Dauber A, Holm IA, Morrison PJ, Keil MF, Lyssikatos C, Smith ED, Sanidad MA, Kelly JC, Dai Z, Mowrey P, Forlino A, Zuffardi O, Stratakis CA. Deletions of the PRKAR1A locus at 17q24.2-q24.3 in Carney complex: genotype-phenotype correlations and implications for genetic testing. J Clin Endocrinol Metab. 2014 Jan; 99(1):E183-8.

6. Dai Z, Kelly JC, Meloni-Ehrig A, Slovak ML, Boles D, Bryke CR, Christacos NC, Schonberg SA, Otani-Rosa JA, Pan Q, Ho AK, Sanders HR, Zhang ZJ, Jones DM, Mowrey PN. Incidence and Patterns of ALK FISH Abnormalities Seen in a Large Unselected Series of Lung Carcinomas. Molecular Cytogenetics, 2012 Dec 3; 5(1):44

Chong JX, Oktay AA, Dai Z, Swoboda KJ, Prior TW, Ober C. A common spinal muscular atrophy deletion mutation is present on a single founder haplotype in the US Hutterites. Eur J Hum Genet, 2011 Oct; 19(10): 1045-51.

Ni W, Ji J, Dai Z, Papp A, Johnson AJ, Ahn S, Farley KL, Lin TS, Dalton JT, Li X, Jarjoura D, Byrd JC, Sadee W, Grever MR, Phelps MA. Flavopiridol Pharmacogenetics: Clinical and Functional Evidence for the Role of SLCO1B1/OATP1B1 in Flavopiridol Disposition. PLoS One, 2010 Nov 1; 5(11): e13792.

7. Bekaii-Saab T, Markowitz J, Prescott N, Sadee W, Heerema N, Wei L, Dai Z, Papp A, Campbell A, Culler K, Balint C, O'Neil B, Lee RM, Zalupski M, Dancey J, Chen H, Grever M, Eng C, Villalona-Calero M. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res, 2009 Sep 15; 15(18): 5895-901

8. Dai Z, Papp AC, Wang D, Hampel H and Sadee W. Genotyping panel for assessing response to cancer chemotherapy. BMC Medical Genomics, 2008, June 11, 1:24

9. Johnson AD, Zhang Y, Papp AC, Pinsonneault J K, Lim JE, Saffen D, Dai Z, Wang D, and Sadee W. Polymorphisms affecting gene transcription and mRNA processing: detection through allelic expression imbalance in human target tissues. Pharmacogenetics and Genomics, 2008, Sep; 18(9): 781-91

10. Blower PE, Chung JH, Verducci JS, Lin S, Park JK, Dai Z, Liu CG, Schmittgen TD, Reinhold WC, Croce CM, Weinstein JN, Sadee W. MicroRNAs modulate the chemosensitivity of tumor cells. Molecular Cancer Therapeutics, 2008 Jan; 7(1): 1-9

11. Smiraglia DJ, Kazhiyur-Mannar R, Oakes CC, Wu YZ, Liang P, Ansari T, Su J, Rush LJ, Smith LT, Yu L, Liu C, Dai Z, Chen SS, Wang SH, Costello J, Ioshikhes I, Dawson DW, Hong JS, Teitell MA, Szafranek A, Camoriano M, Song F, Elliott R, Held W, Trasler JM, Plass C, Wenger R. Restriction landmark genomic scanning (RLGS) spot identification by second generation virtual RLGS in multiple genomes with multiple enzyme combinations. BMC Genomics, 2007 Nov; 30;8: 446

12. Liu R, Blower PE, Pham AN, Fang J, Dai Z, Wise C, Green B, Teitel CH, Ning B, Ling W, Lyn-Cook BD, Kadlubar FF, Sadée W, Huang Y. Cystine-glutamate transporter SLC7A11 mediates resistance to geldanamycin but not to 17-(allylamino)-17-demethoxygeldanamycin. Molecular Pharmacology, 2007 Dec; 72(6): 1637-46

13. Blower PE, Verducci JS, Lin A, Zhou J, Chung JH, Dai Z, Liu CG, Reinhold W, Lorenzi PL, Kaldjian EP, Croce CM, Weinstein JN and Sadee W. MicroRNA expression profiles for the NCI-60 cancer cell panel. Molecular Cancer Therapeutics, 2007 May; 6(5): 1483-91

14. Huang Y, Blower PE, Liu R, Dai Z, Pham AN, Moon H, Fang J, and Sadée W. Chemogenomic analysis identifies geldanamycins as substrates and inhibitors of ABCB1. Pharmaceutical Research, 2007 Sep; 24(9): 1702-12

15. Dai Z, Huang Y, Sadee W, and Blower P. Chemoinformatics analysis identifies cytotoxic compounds susceptible to chemoresistance mediated by glutathione and cystine/ glutamate transport system [pic]. Journal of Medicinal Chemistry, 2007 Apr 19; 50(8): 1896-1906

16. Dai Z, Sadee W and Blower P. Chemogenomics of sensitivity and resistance to anticancer drugs. Current Pharmacogenomics, 2007 Mar; 5(1): 11-19

17. Cao X, Fang L, Gibbs S, Huang Y, Dai Z, Wen P, Zheng X, Sadee W, Sun D. Glucose uptake inhibitor sensitizes cancer cells to daunorubicin and overcomes drug resistance in hypoxia. Cancer Chemotherapy and Pharmacology, 2007 Mar; 59(4): 495-505

18. Dai Z, Liu S, Marcucci G, Sadee W. 5-Aza-2'-deoxycytidine and depsipeptide synergistically induce expression of BIK (BCL2-interacting killer). Biochemical and Biophysical Research Communications, 2006 Dec 15; 351(2): 455-61

19. Wang Y, Dai Z, Sadee W and Hancock W. A Pharmacoproteomics Study of the Cancer Cell Line EKVX using Capillary-LC/MS/MS. Molecular Pharmaceutics, 2006 Sep-Oct; 3(5): 566-78

20. Dai Z, Barbacioru C, Huang Y and Sadee W. Prediction of anticancer drug potency from expression of genes involved in growth factor signaling. Pharmaceutical Research, 2006 Feb; 23(2): 336-49

21. Sadee W and Dai Z. Pharmacogenetics/genomics and Personalized Medicine. Human Molecular Genetics, 2005 Oct 15; 14 Suppl 2: R207-14

22. Dai Z and Huang Y (equal contribution), Barbacioru C and Sadee W. Cystine/ glutamate transporter SLC7A11 in cancer chemosensitivity and chemoresistance. Cancer Research, 2005, Aug 15; 65(16): 7446-54

23. Xiao JJ, Huang Y, Dai Z, Sadée W, Chen J, Liu S, Marcucci G, Byrd J, Covey JM, Wright J, Grever M, and Chan KK. Chemoresistance to depsipeptide FK228 is mediated by reversible MDR1 induction in human cancer cell lines. Journal of Pharmacology and Experimental Therapeutics, 2005, 2005 Jul; 314(1): 467-75

24. Xiao JJ, Foraker AB, Swaan PW, Liu S, Huang Y, Dai Z, Sadée W, Byrd J, Marcucci G and Chan KK. Efflux of Depsipeptide FK228 (FR901228, NSC-630176) is mediated by both Pglycoprotein and MRP1. Journal of Pharmacology and Experimental Therapeutics, 2005, Apr; 313(1): 268-76

25. Yu L, Liu C, Vandeusen J, Becknell B, Dai Z, Wu YZ, Raval A, Liu TH, Ding W, Mao C, Liu S, Smith LT, Lee S, Rassenti L, Guido Marcucci G, Byrd J, Caligiuri MA and Plass C. Global assessment of promoter methylation in a murine model of cancer identifies ID4 as a putative novel tumor suppressor gene in human leukemia. Nature Genetics, 2005, Mar; 37(3): 265-74

26. Huang Y, Blower PE, Yang C, Barbacioru C, Dai Z, Zhang Y, Xiao JJ, Chan KK & Sadée W. Correlating gene expression with chemical scaffolds of cytotoxic agents: ellipticines as substrates and inhibitors of MDR1 (ABCB1). Pharmacogenomics Journal, 2005, Pharmacogenomics J. 2005; 5(2): 112-25

27. Yu L, Liu C, Bennett K, Wu YZ, Dai Z, Vandeusen J, Opavsky R, Raval A, Trikha P, Rodriguez B, Becknell B, Mao C, Lee S, Davuluri RV, Leone G, Van den Veyver IB, Caligiuri MA, Plass C. A NotI-EcoRV promoter library for studies of genetic and epigenetic alterations in mouse models of human malignancies. Genomics, 2004 Oct; 84 (4): 647-60

28. Dai Z, Huang Y and Sadee W. Growth factor signaling and resistance to cancer chemotherapy. Current Topics in Medicinal Chemistry, September 2004, vol. 4, no. 13, pp. 1347-56

29. Huang Y, Anderle P, Bussey KJ, Barbacioru C, Shankavaram U, Dai Z, Reinhold WC, Papp A, Weinstein JN and Wolfgang Sadée W. Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance, Cancer Research, 2004, June 15; 64(12): 4294-301

30. Dai Z, Popkie AP, Zhu WG, Timmers CD, Raval A, Tannehill-Greg S, Morrison CD, Auer H, Kratzke RA, Leone GW, Rosol T, Otterson GA and Plass C. Bone morphogenic protein 3B (BMP3B) silencing in non-small cell lung cancer. Oncogene, 2004 Apr. 29; 23(20): 3521-9

31. Zhu WG, Hileman T, Ke Y, Wang P, Lu S, Duan W, Dai Z, Tong T, Villalona-Calero MA, Plass C, Otterson GA. 5-aza-2'-deoxycytidine activates the p53/p21Waf1/Cip1 pathway to inhibit cell proliferation. Journal of Biological Chemistry, 2004 Apr. 9; 279(15):15161-6

32. Li J, Zhang Z, Dai Z, Popkie AP, Plass C, Morrison C, Wang Y, You M. RASSF1A promoter methylation and Kras2 mutations in non small cell lung cancer. Neoplasia, 2003 Jul-Aug; 5(4):362-6

33. Zhu WG, Srinivasan K, Dai Z, Duan W, Druhan LJ, Ding H, Yee L, Villalona-Calero MV, Plass C, and Otterson GA. Methylation of adjacent CpG sites affects Sp1/Sp3 binding and activity in the p21(Cip1) promoter. Molecular and Cellular Biology, 2003 Jun; 23(12): 4056-65

34. Dai Z, Zhu WG, Morrison CD, Brena RM, Smiraglia DJ, Raval A, Wu YZ, Rush LJ, Ross P, Molina JR, Otterson GA, and Plass C. A comprehensive search for DNA amplification in lung cancer identifies inhibitors of apoptosis cIAP1 and cIAP2 as candidate oncogene. Human Molecular Genetics, 2003, April 1; 12(7): 791-801

35. Li J, Zhang Z, Dai Z, Plass C, Morrison C, Wang Y, Wiest JS, Anderson MW, and You M. LOH of chromosome 12p correlates with Kras2 Mutation in Non-Small Cell Lung Cancer. Oncogene, 2003 Feb 27; 22(8): 1243-6

36. Smiraglia DJ, Smith LT, Lang JC, Rush LJ, Dai Z, Schuller DE, Plass C. Differential targets of CpG island hypermethylation in primary and metastatic head and neck squamous cell carcinoma (HNSCC). Journal of Medical Genetics, 2003 Jan; 40(1):25-33

37. Dai Z, Weichenhan D, Wu YZ, Hall J, Rush LJ, Smith L, Smiraglia DJ, Yu L, Frühwald MC, Davuluri R and Plass C. An AscI boundary library for the studies of genetic and epigenetic alterations in CpG islands. Genome Research, 2002 Oct.; 12(10) 1591-8

38. Zhu WG, Dai Z, Ding H, Srinivasan K, Hall J, Duan W, Villalona-Calero MA, Plass C, Otterson GA. Increased expression of unmethylated CDKN2D by 5-aza 2’deoxycytidine in human lung cancer cells. Oncogene, 2001 Nov 22; 20(53): 7787-96

39. Dai Z, Lakshmanan RR, Zhu WG, Smiraglia DJ, Rush LJ, Frühwald MC, Brena RM, Li B, Wright FA, Ross P, Otterson GA, Plass C. Global Methylation Profiling of Lung Cancer Identifies Novel Methylated Genes. Neoplasia, 2001 Jul-Aug; 3(4):314-23

40. Frühwald MC, O’Dorisio MS, Dai Z, Tanner SM, Balster DA, Gao X, Wright FA, Plass C. Aberrant promoter methylation of previously unidentified target genes is a common abnormality in medulloblastomas--implications for tumor biology and potential clinical utility. Oncogene, 2001 Aug 16; 20(36): 5033-42

41. Frühwald MC, O’Dorisio MS, Laura ST, Dai Z, Wright FA, Paulus W, Jürgens H, Plass C. Hypermethylation as a Potential Prognostic Factor and a Clue to a Better Understanding of the Molecular Pathogenesis of Medulloblastoma - Results of A Genomewide Methylation Scan. Klin Padiatr, 2001 Jul-Aug; 213(4): 197-203

42. Smiraglia DJ, Rush LJ, Frühwald MC, Dai Z, Held WA, Costello JF, Lang JC, Eng C, Li B, Wright FA, Caligiuri MA, Plass C. Excessive CpG island hypermethylation in cancer cell lines versus primary human malignancies. Human Molecular Genetics, 2001 Jun 15; 10(13): 1413-9

43. Rush LJ, Dai Z, Smiraglia DJ, Gao X, Wright FA, Fruhwald M, Costello JF, Held WA, Yu L, Krahe R, Kolitz JE, Bloomfield CD, Caligiuri MA, Plass C. Novel methylation targets in de novo acute myeloid leukemia with prevalence of chromosome 11 loci. Blood, 2001 May 15; 97(10): 3226-33

44. Frühwald M, O'Dorisio MS, Dai Z, Rush LJ, Krahe R, Smiraglia DJ, Pietsch T, Elsea SH, and Plass C. Aberrant hypermethylation of the major breakpoint cluster region in 17p11.2 in medulloblastomas but not supratentorial PNETs. Genes Chromosomes and Cancer, 2001 Jan; 30:38-47

45. Smiraglia DJ, Frühwald MC, Costello JF, McCormick SP, Dai Z, Peltomaki P, O’Dorisio MS, Cavenee WK, Plass C. A new tool for the rapid cloning of amplified and hypermethylated human DNA sequences from restriction landmark genome scanning gels. Genomics, 58:254-262, 1999

46. Dai Z, Jiang XP, Liu KD. Genes that involved in negative regulation of tumor metastasis. Foreign Medical Science Oncology Section, 21 (supplement): 32-35, 1994

ABSTRACTS FOR POSTERS OR ORAL PRESENTATIONS:

1. Dai Z, Alexander JJ, Mighion LC, Whitt Z, Bean LJH, Hegde M, Examining Gene: Disease causality; Do heterozygous loss-of-function variants in the MYH8 gene cause phenotypes? A study of 18 cases in NGS panels. ACMG Annual Clinical Genetics Meeting, Tampa, FL, March 8-12, 2016

2. Bean LJH, Garber K, Billotte B, Collins C, Alexander J, Ankala A, Askree H, Dai Z, Tanner A, Vasudevan S, da Silva C, Hegde MR, EmVClass: A Clinical Laboratory’s Web-based Tool that Facilitates Variant Classification Dialog. ACMG Annual Clinical Genetics Meeting, Tampa, FL, March 8-12, 2016

3. Askree SH, Jinnah H, Bean LJH, Collins C, Alexander J, Tanner AK, Ankala A, Dai Z, and Hegde MR, Next Generation Testing for Isolated & Combined Dystonia. ACMG Annual Clinical Genetics Meeting, Tampa, FL, March 8-12, 2016

1. Meloni-Ehrig AM, Curtis CA, Mahoney SP, Bohls N, Kraemer C, Stone E, Braun J, Siragusa K, Stone P, Ramos A, Thompson C, Daugherty F, Conklin S, An C, Lalarukh Aftab L, Hammami A, Schniederjan S, Lou Z, Dai Z, Lyons J, Hertzberg L, Significance of Conventional Cytogenetics in Improving the Diagnosis and Prognosis of Lymphoid Neoplasms in Tissue Samples, 57th ASH Annual Meeting & Exposition, Orlando, FL, December 5-8, 2015

2. Dai Z, Bean LJH, Collins C, Hussain Askree S, Alexander JJ, Hegde M, Tanner A, Next Generation Sequencing as a Diagnostic Tool for Hereditary Breast and Ovarian Cancer, AMP 2015 Annual Meeting, Realizing the Dream of Precision Medicine, Austin, TX, November 5-7, 2015

3. Bryke CR, McDermott DH, Gao JL, Liu Q, Siwicki M, Martens C, Jacobs P, Velez D, Yim E, Hsu N, Dai Z, Marquesen MM, Stregevsky E, Kwatemaa N, Theobald N, Long Priel DA, Pittaluga S, Raffeld MA, Calvo KR, Maric I, Desmond R, Holmes KL, Kuhns DB, Balabanian K, Bachelerie F, Porcella SF, Malech HL, and Murphy PM, WHIM syndrome cured by chromothripsis, The Cancer Genomics Consortium-CAGdb 6th Summer Meeting, Denver, Colorado, August 3-5, 2015

4. Dai Z, Bunke B, Kunig D, Vena NA, Bean LJH, Collins C, Coffee B and Rudd MK, Incidental copy number findings in targeted microarray gene testing explain clinical phenotypes, 43rd Biennial American Cytogenetics Conference, Asheville, NC, May 4-7, 2014

5. Huang D, Bryke C, Dai Z, Kelly J, Cho Lee JC, Hsu YH, Rhonda Mackendrick R, Otani J, Mowrey PN. Chromothripsis of 21q including deletion of 5’ RUNX1 Revealed by Oligo-SNP Array in a Patient with Acute Myeloid Leukemia and a Constitutional Ring Chromosome 21. ACMG Annual Clinical Genetics Meeting, Nashville, TN, March 25-29, 2014

6. Hughes E, Otani-Rosa J, Jahn J, Boles D, Schonberg S, Dai Z, Ross L, Mowrey PN. Microarray Analysis Performed on a 14 Month Old Girl with a Normal Karyotype Reveals an Unbalanced Rearrangement Resulting in Deletion of 4p and Duplication of 11p. Association of Genetic Technologists, 38th Annual Meeting, Las Vegas Nevada, June 6-8, 2013

7. Dai Z, Kelly JC, Martin AD, Farkas AC, Zand DJ, Otani-Rosa J, Baugh BM, Adams CM, Hsu Y-H and Mowrey PN. Direct Evidence Suggests that Deletions of the Distal Portion of the Williams Syndrome Region Are Contributory to the Clinical Phenotype. ACMG Annual Clinical Genetics Meeting, Phoenix, AZ, March 19-23, 2013

8. Huang D, Dai Z, Kelly JC, Crain C, Wheeler PG, Sahoo T, Martin AD, Adams CM, Simanivanh M, Baugh BM and Mowrey PN. Deletion of HDAC4 Causes Brachydactyly but not Mental Retardation in a Family. ACMG Annual Clinical Genetics Meeting, Phoenix, AZ, March 19-23, 2013

9. Slovak ML, Hsu Y-H, Otani-Rosa JA, Jahn JA, Dai Z, Sanidad M, Mowrey PN, Jones D. Microarray-based genomic profiling facilitates genetic subgrouping and detects critical submicroscopic aberrations associated with prognosis in pediatric acute lymphoblastic leukemia (ALL). ASH, Dec. 2012.

10. Christacos NC, Schonberg, S., Dai Z, Bryke C, Kelly J, Wallenhorst E, Sullivan K, Adams C, Hsu,Y, Walker H, Simanivanh T, Mowrey PA. Cryptic Derivative Chromosome 12 Detected by Oligo-SNP Array. American Society of Human Genetics annual meeting, Nov. 2012.

11. Otani-Rosa JA, Broderick L, Heritage DW, Schonberg SA, Dai Z, Slovak ML, Berg R, Sanidad M, Burrington C, and Mowrey PN. Neocentromeres identified in four constitutional and one oncology karyotypes containing marker chromosomes. AGT 37th Annual Meeting, June 2012.

12. Heritage DW, JA Otani-Rosa JA, Gilliam A, SA Schonberg SA, Dai Z, Martin A, Koch SW, A Paik A, and Mowrey PN. A rare tetragametic chimera with 47,XY,+18//46,XX karyotype. AGT 37th Annual Meeting, June 2012.

13. Dai Z, Kelly JC, Meloni-Ehrig A, Slovak ML, Boles D, Christacos NC, Schonberg SA, Otani-Rosa JO, Pan Q, Ho AK, Jones DM, Mowrey PN. Incidence and patterns of ALK FISH abnormalities seen in a large unselected series of lung carcinomas. ACMG Annual Clinical Genetics Meeting, Charlotte, NC, March 27-31, 2012

14. Christacos N, Schonberg S, Dai Z, Boles D, Kelly J, Solvak ML, Burks K, Simanivanh T, Mowrey PN. IsoUPD as a mechanism of fetal rescue detected by Oligo-SNP array. The 12th International Congress of Human Genetics and the American Society of Human Genetics 61st Annual Meeting, Montreal, Canada, October 11-15, 2011

15. Dai Z, Meloni-Ehrig AM, Zhou J, Otani-Rosa JA, Sanidad MA, Mowrey PN, Muir JM, Andriko JW, Schonberg SA, Jones DM. Translocation (X;14)(q28;q11.2) in T-cell prolymphocytic leukemia (T-PLL): four cases with similar secondary genetic changes as those observed in TCL1-translocated T-PLL. ACMG 2011 Annual meeting, Vancouver, BC Canada, March 16-20, 2011

16. Chong JX, Oktay AA, Dai Z, Swoboda K, Prior TW, Ober C. A Common Spinal Muscular Atrophy (SMA) Deletion Mutation is Present on a Single Founder Haplotype in the U.S. Hutterites. ASHG 2010 Annual Meeting, Washington DC, November 2-6, 2010

17. Hanna J, Dai Z, Heerema NA and Walker A. Myelodysplastic syndrome (MDS) with 5q- evolves into complex karyotype including a ring chromosome 11 and derivative 11 with homogeneously staining regions. AGT 35th Annual Meeting, June 3-5, 2010. Phoenix, Arizona, published in The Journal of the Association of Genetic Technologists 36: 155, 2010

18. Chen X, Jones J, Dai Z, Cole C, Smith A, Williams M, Messaros K, Gardner M, Bruney J, Heerema NA. Variant BCL3 /immunoglobulin light chain gene (IgL) and BCL11a/IgH translocations in a chronic lymphocytic leukemia (CLL) patient. AGT 34th Annual Meeting, Jacksonville, FL, June 25-27, 2009

19. Koesters N, Parker A, Dai Z, Gardner M, Hanna J, Grimaldi B, Marcucci G, Blum W, Klisovic R, Heerema NA. ETV6 rearrangements in myeloid malignancies. AGT 33rd Annual Meeting. JW Marriott -Houston, Texas, June 12-14, 2008

20. Davis S, Andritsos L, Blum W, Z. Dai Z, Grimaldi B, Smith A, Heerema NA. A cryptic t(7;21)(p22;q22) in a patient with acute myelogenous leukemia. AGT 33rd Annual Meeting, JW Marriott -Houston, Texas, June 12-14, 2008

21. Dai Z and Heerema NA. BCL3 and immunoglobulin heavy or light chain gene translocation in chronic lymphocytic leukemia patients. Annual Regional Genetics Conference, Cincinnati Children’s Hospital Medical Center, April 25-26, 2008

22. Richardson D, Dai Z, Papp A, Hampel H, de la Chapelle A, Wolfgang Sadee. Allele-specific loss of heterozygosity of APC in colorectal cancer. The Ohio State Medical Center's Seventh Annual Research Day, April 10, 2008

23. Phelps MA, Wu D, Dai Z, Hurh E, Johnson AJ, Farley KL, Schaaf LJ, Sadee W, Lin TS, Byrd JC, Grever MR, Dalton JT. Population Pharmacokinetics, Pharmacodynamics and Pharmacogenomics of Flavopiridol with a Clinically Active Dosing Schedule in Patients with Chronic Lymphocytic Leukemia. The American Association for Cancer Research 98th annual meeting, Los Angeles, CA, April 14-18, 2007

24. Dai Z, Papp A, Wang D, helps M, Dalton JT and Sadee W. SNPlex Genotyping of Genes Related to Cancer Risk and Treatment Response to Chemotherapy. The 9th Annual Comprehensive Cancer Center Scientific Meeting, Columbus Convention Center, Columbus, OH, February 23, 2007

25. Dai Z, Papp A, Wang D and Sadee W. Large Scale Genotyping for Cancer Related Genes Using SNPlex. The 8th Annual Comprehensive Cancer Center Scientific Meeting, Columbus, Ohio, 2006

26. Cao X, Ping, P, Dai Z, Huang Y, Wang PG, Sadee W and Sun D. Expression of GLUT1 in tumors promotes cancer cell survival. American Association of Pharmaceutical Sciences (AAPS) Annual Meeting, Nashville, TN, November 6-10, 2005

27. Dai Z, Huang Y, Barbacioru C and Sadee W. Identification of growth factor signaling that determines chemoresistance. The American Association for Cancer Research 95th annual meeting, Orlando, FL, March 26-31, 2004

28. Huang Y, Dai Z, Anderle P, Barbacioru C, John N. Weinsrein and Sadee W. Validating novel chemosensitivity and chemoresistance genes identified by correlation of gene expression and anticancer drug potency. The American Association for Cancer Research 95th annual meeting, Orlando, FL, March 26-31, 2004

29. Huang Y, Dai Z and Sadee W. siRNA-induced transporter gene silencing in cancer cells: validation of novel drug transporters identified by gene expression-drug potency correlations. American Association of Pharmaceutical Scientists (AAPS) annual meeting, Salt Palace Convention Center, Salt Lake City, Utah, October 26-30, 2003

30. Dai Z, Zhu WG, Popkie AP, Wali A, Pass H, Timmers CD, Leone GW, Niehans GA, Kratzke RA, Otterson GA, Plass C. Promoter methylation and silencing of bone morphogenetic protein 3B (BMP3B) in non-small cell lung cancer identifies a novel lung cancer gene on 10q11. Proceedings of the American Association for Cancer Research 93rd annual meeting, Page 469, San Francisco, California, April 6-10, 2002

31. Zhu WG, Dai Z, Srinivasan K, Ding H, Duan W, Villalona-Calero MA, Plass C, Otterson GA. Methylated Sp1 binding sites are responsible for p21 silencing. Proceedings of the American Association for Cancer Research 93rd annual meeting, Page 1115, San Francisco, California, April 6-10, 2002

32. Dai Z, Zhu WG, Popkie AP, Wali A, Pass H, Timmers CD, Leone GW, Niehans GA, Kratzke RA, Otterson GA, Plass C. Promoter methylation and silencing of bone morphogenetic protein 3B (BMP3B) in non-small cell lung cancer. Bennett Graduate Research Day, Columbus, OH, February 19, 2002

33. Abdel-Rahman MH, Yates AJ, Prior T, Yates A, Dai Z, Plass C, and Krahe R. Molecular genetic dissection of chromosome 1q32 amplicon in human gliomas: identification of multiple candidate oncogenes and genetic pathways in brain tumorigenesis. Cancer Detection and prevention online (), 6th International Symposium on Predictive Oncology and Intervention Strategies in Paris, Feb. 9, 2002

34. Zhu WG, Dai Z, Srinivasan K, Ding H, Duan W, Villalona-Calero MA, Plass C, Otterson GA. Methylated Sp1 binding sites are responsible for p21 silencing. Genomics and Cancer Biology, The Fourth Annual Comprehensive Cancer Center Scientific Meeting, page 48. Dublin, OH, Jan. 11, 2002

35. Smiraglia DJ, Smith LT, Rush LJ, Dai Z, Lang JC, Schuller DE, Plass C. Variable CpG island hypermethylation phenotypes in primary and metastatic head and neck squamous cell carcinoma. Genomics and Cancer Biology, The Fourth Annual Comprehensive Cancer Center Scientific Meeting, page 60. Dublin, OH, Jan. 11, 2002

36. Dai Z. Global methylation profiling of lung cancer specimens reveals novel methylated genes. Proceeding of 2001 (15th Annual) Edward F. Hayes Graduate Research Forum, page 206-218. The Ohio State University. April 21, 2001

37. Dai Z, Zhu WG, Otterson GA, Plass C. Global methylation screening identifies novel methylated genes in lung cancer. OSU/UC Pathology Research Conference 2001, Columbus, OH. May 11, 2001

38. Abdel-Rahman M, Dai Z, Prior T, Yates A, Plass C, and Krahe R. Amplification and overexpression of PI3KC2B, a candidate oncogene in 1q32, in a case with low-grade glioma. European Journal of Human Genetics. 9:127. 10th international congress of human genetics. Vienna, Austria. May 15-19, 2001

39. Zhu WG, Dai Z, Lakshmanan R, Plass C, Otterson GA. Inhibition of histone deacetylase and DNA methytransferase activity differentially affects p16INK4a and p19INK4d protein expression. Proceedings of the American Association for Cancer Research 92nd annual meeting, Page 61, New Orleans, LA. March 24-28, 2001

40. Smiraglia DJ, Frühwald MC, Rush LJ, Dai Z, Smith LT, Plass C. CpG island hypermethylation in cancer – results of a genome scanning approach in multiple human tumors. The Ohio State University Comprehensive Cancer Center Third Annual Scientific Meeting, Page 37, New Embassy Suites Hotel. Dublin, OH. January 24, 2001

41. Fruhwald M., Dai Z., Tanner SM., Balster DA, Wright FA, Plass C. Aberrant hypermethylation of novel rather than known methylation target genes in malignant brain tumors of childhood. Eur J Pediatr, 160:R20, 2001

42. Plass C, Frühwald MC, Rush LJ, Dai Z, Smith LT, Smiraglia DJ. The contribution of DNA methylation to oncogenesis – results of a genome scanning approach in multiple human tumors. Oncogenomics conference — Dissecting Cancer Through Genome Research, Page 80; Tucson, AZ. January, 2001

43. Dai Z, Ross P, Gordon R, Otterson GA, Plass C. Identification of Hypermethylated CpG Islands in Non-Small Cell Lung Cancer and Related Aberrant Gene Transcription. 12th annual molecular biology & cancer genetics program stone lab meeting. Page 23, September 15-17, 2000

44. Dai Z, Ross P, Otterson GA, Plass C. Global DNA Methylation Changes in Primary Lung Cancer. Gordon Research Conference. Cancer Genetics and Epigenetics. Ventura, CA. February 20-25, 2000

45. Fruhwald MC, O'Dorisio MS, Dai Z, Wright F, Plass C. Hypermethylation of multiple gene loci in medulloblastomas - potential clinical implications. International Society of Paediatric Oncology SIOP, Med Pediatr Oncol 35:235 (P54), 2000

46. Fruhwald MC, O'Dorisio MS, Dai Z, Wright F, Plass C. Promoter hypermethylation in medullo-blastomas - aspects of tumor biology and potential clinical utility. Neurooncology, 2:S79, 2000

47. Fruhwald MC, O'Dorisio MS, Dai Z, Smiraglia DJ, Plass C. Hypermethylation of the major chromosomal breakpoint in medulloblastoma. Neurooncology 1:311 (74), 1999

48. Dai Z, Liu KD, Lu JZ, Li J, Liao Y, Chen J, Lei L, Tang ZY. Phase I clinical trial of targeting therapy using 131I-anti-HbxAg monoclonal antibody in patients with primary liver cancer. Recent progress in liver cancer and hepatitis — Proceedings of 1996 Shanghai International Symposium on Liver Cancer and Hepatitis. Page 188, March 5-7, 1996

................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download